{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-178970","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.706726+00:00","generated_at":"2026-05-17T14:41:07.263620+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Spero reports Q2 results and tebipenem Phase 3 success; plans FDA filing in 2H 2025","bullets":["Q2 2025 net loss $1.7M ($0.03/share) vs $17.9M ($0.33) in Q2 2024; revenue $14.2M up from $10.2M.","Phase 3 PIVOT-PO trial of tebipenem HBr in cUTI met primary endpoint; IDMC stopped early for efficacy.","Spero and GSK plan to submit data to FDA in 2H 2025; potential milestone payments adjusted to up to $101M from $150M.","Cash $31.2M at June 30 plus $23.8M GSK milestone received Aug 2025; runway expected into 2028.","Esther Rajavelu appointed CEO/President effective May 2, 2025, continuing as CFO."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-178970","json":"https://secwatch.observer/filing/0001193125-25-178970.json","markdown":"https://secwatch.observer/filing/0001193125-25-178970.md","text":"https://secwatch.observer/filing/0001193125-25-178970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525178970/0001193125-25-178970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312525178970/d97572d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:41:07.263620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}